---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-289768"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:07:53.267844+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IKT advances IKT-001 to global pivotal Phase 3 in PAH; ATM prospectus terminated

## Summary
- IMPROVE-PAH Phase 3 trial for IKT-001 in pulmonary arterial hypertension expected to start Q1 2026 across up to 180 sites.
- Adaptive two-part design: Part A (140 pts, primary endpoint PVR at Week 24) and Part B (346 pts, primary endpoint 6MWD at Week 24).
- Prior Phase 2b plan replaced after FDA Type C meeting; company cites advantages of uninterrupted enrollment and dose titration.
- ATM prospectus terminated with no sales made; Sales Agreement with Jefferies remains in effect without further sales pending new filings.

## SEC filing metadata
- accession: 0001193125-25-289768
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/0001193125-25-289768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/d20255d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-289768
- JSON: https://secwatch.observer/filing/0001193125-25-289768.json
- Plain text: https://secwatch.observer/filing/0001193125-25-289768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.